ACP-ASIM Information: Membership
Change of
Address Residency
Database CME
Career Resource
Center Where we stand
Discussion
Groups Annals
Committees
Computers/Medicine
IM
Bookmarks Medline
|
|
Missouri Resident Poster Competition 1999
|
Second
Place
Clinical Division |
|
|
Gentiana Voinescu M.D.
Univ.
of Missouri--Columbia
Prothrombin
20210A gene mutation: a common abnormality causing an unusual
abdominal
venous thrombosis
A mutation in the prothrombin gene (GV
A20210) has been associated with higher plasma prothrombin levels
and an increased tendency for venous thrombosis. We present a
39-year-old healthy white female who was seen in a local emergency
room seven days prior to admission to our hospital, complaining of
gradual onset of midepigastric pain, mild nausea and low grade
fever. At the 2-day follow up with her primary care physician, an
ultrasound of the abdomen was diagnostic for extensive thrombosis of
the portal and superior mesenteric vein. She was transferred to our
facility after laboratory tests were drawn to assess her for
hypercoagulable states. These included: protein C, protein S,
anticardiolipin antibodies, activated protein C resistance and lupus
anticoagulant.
On admission the patient denied abdominal trauma, previous
clotting problems in her or her family, smoking, birth control pills
usage, weight loss or previous pancreatic problems. The patient was
on no medications. Physical examination revealed moderate epigastric
tenderness, no rebound or guarding. The patient was started on
intravenous heparin. A work-up for myeloproliferative disorders,
tumors, and pancreatitis was negative. Findings included a normal
complete blood count, amylase, lipase, chest X-ray, and mammogram.
Computerized tomography of the abdomen showed occlusion of the
superior mesenteric vein and portal vein. Since the hypercoagulable
profile was negative to date, a polymerase chain reaction assay for
prothrombin 20210A gene mutation was obtained. This revealed that
the patient was heterozygous for the mutation. She began coumadin
therapy. The computerized tomography of the abdomen repeated after
six weeks of anticoagulation demonstrated interval reconstitution of
blood flow through the portal vein and improvement in size of
superior mesenteric vein thrombosis.
Laboratory tests to define the hypercoagulable state are
continually being developed. This newly described mutation appears
to be a frequent, although often overlooked cause of unexplained
thrombosis. It is associated with at least a three-fold risk of
developing venous thrombosis.
Keywords: thrombosis, prothrombin 20210A gene
mutation, risk factors.
|